Watertime, Author at PsyNews.com

Home Authors Posts by Watertime

475 POSTS 0 COMMENTS

Momentum Amidst Tumult: The FDA Reshuffle, Approval Timelines, and the Compass-Usona...

Field Notes #1: Psychiatrists, Regulators, Ibogaine, and the Race for Psilocybin...

At the Federal Psychedelic Medicine Summit, the Mood Was Urgent, Practical,...

Bit Yaden on Preparing the Next Generation of Psychiatrists for a...

“If I can’t change my views based on evidence, then why...

Q4 2025: Oregon Psilocybin Services Update

Psilocybin for Chronic Suicidal Ideation: Scott T. Aaronson on Safety, an...

Music in Psychedelic-Assisted Therapy: An Introduction to Sound, Playlist Curation, and...

April 2026 Psychedelic Bill Round-up

Travis Tyler Fluck: Denver Mushroom Decriminalization, Mutual Aid, and the Future...

12 3...48 Page 1 of 48

EDITOR PICKS

Momentum Amidst Tumult: The FDA Reshuffle, Approval Timelines, and the Compass-Usona...

Field Notes #1: Psychiatrists, Regulators, Ibogaine, and the Race for Psilocybin...

At the Federal Psychedelic Medicine Summit, the Mood Was Urgent, Practical,...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Watertime

Momentum Amidst Tumult: The FDA Reshuffle, Approval Timelines, and the Compass-Usona...

Field Notes #1: Psychiatrists, Regulators, Ibogaine, and the Race for Psilocybin...

At the Federal Psychedelic Medicine Summit, the Mood Was Urgent, Practical,...

Bit Yaden on Preparing the Next Generation of Psychiatrists for a...

“If I can’t change my views based on evidence, then why...

Q4 2025: Oregon Psilocybin Services Update

Psilocybin for Chronic Suicidal Ideation: Scott T. Aaronson on Safety, an...

Music in Psychedelic-Assisted Therapy: An Introduction to Sound, Playlist Curation, and...

April 2026 Psychedelic Bill Round-up

Travis Tyler Fluck: Denver Mushroom Decriminalization, Mutual Aid, and the Future...

EDITOR PICKS

Momentum Amidst Tumult: The FDA Reshuffle, Approval Timelines, and the Compass-Usona...

Field Notes #1: Psychiatrists, Regulators, Ibogaine, and the Race for Psilocybin...

At the Federal Psychedelic Medicine Summit, the Mood Was Urgent, Practical,...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY